SCHEMBL629530

SCHEMBL629530

C=CCCC(O)C(O)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.39
PDE4A P27815 1/20 0.37
PGD P52209 1/20 0.36
MAPT P10636 2/20 0.35
ABCC4 O15439 1/20 0.35
ALDH1A1 P00352 2/20 0.33
CYP2C9 P11712 1/20 0.32
DDAH1 O94760 1/20 0.32
GRIK1 P39086 2/20 0.31
GRIK2 Q13002 2/20 0.31
FAAH O00519 1/20 0.31
USP2 O75604 1/20 0.31
CYP3A4 P08684 1/20 0.31
HPGD P15428 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CYP2C19 P33261 2/20 0.31
CPA1 P15085 1/20 0.31
SLC6A2 P23975 1/20 0.30
SLC6A4 P31645 1/20 0.30
BLM P54132 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15698565 1.00 TSHR (0.39) TSHRPDE4APGDMAPTABCC4
SCHEMBL27696125 1.00 TSHR (0.39) TSHRPDE4APGDMAPTABCC4
SCHEMBL6120459 0.98 TSHR (0.38) TSHRPDE4APGDMAPTABCC4
SCHEMBL4539895 0.98 TSHR (0.38) TSHRPDE4APGDMAPTABCC4
SCHEMBL27702751 0.98 TSHR (0.38) TSHRPDE4APGDMAPTABCC4
SCHEMBL28068419 0.87 MAPT (0.42) TSHRPDE4APGDMAPTABCC4
SCHEMBL3892239 0.85 MAPT (0.41) TSHRPDE4APGDMAPTABCC4
SCHEMBL4538038 0.83 LMNA (0.41) TSHRMAPTABCC4CYP3A4NFKB1
SCHEMBL20819989 0.80 MAPT (0.34) MAPTABCC4ALDH1A1DDAH1GRIK1
SCHEMBL22552623 0.80 MAPT (0.34) MAPTABCC4ALDH1A1DDAH1GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1536999-B Crystalline forms of fluvastatin sodium CIBA SC HOLDING AG 2012-08-08 CN claimed
WO-2012063115-A2 PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM VIA NOVEL AMINE INTERMEDIATE JUBILANT LIFE SCIENCES LTD. (IN) 2012-05-18 WO claimed
WO-2010030201-A2 STABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING A PHARMACEUTICALLY ACCEPTABLE SALT OF [(E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2- [METHYL(METHYLSULFONYL)AMINO]PYRIMIDINE-5-YL] (3R, 5S) - 3,5 DIHYDROXYHEPT-6- ENOIC ACID ZAKLADY FARMACEUTYCZNE POLPHARMA SA (PL) 2010-03-18 WO claimed
JP-2007507417-A 2007-03-29 JP claimed
EP-1667974-A1 PROCESS FOR PRODUCING HIGH PURITY 3,5-DIHYDROXY-6-HEPTENOIC ACID DERIVATIVE Nissan Chemical Industries, Ltd. (JP) 2006-06-14 EP claimed
EP-1539698-A1 METHOD FOR PRODUCING A 3,5-DIHYDROXY-6-HEPTENOATE Nissan Chemical Industries, Ltd. (JP) 2005-06-15 EP claimed
WO-2005033083-A1 PROCESS FOR PRODUCING HIGH PURITY 3,5-DIHYDROXY-6-HEPTENOIC ACID DERIVATIVE NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2005-04-14 WO claimed
CN-1536999-A Crystalline forms of fluvastatin sodium �������⻯ѧƷ�ع����޹�˾ 2004-10-13 CN claimed
WO-2004026838-A1 METHOD FOR PRODUCING A 3,5-DIHYDROXY-6-HEPTENOATE NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2004-04-01 WO claimed
EP-1339409-A1 USE OF ROSUVASTATIN (ZD-4522) IN THE TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AstraZeneca AB (SE) 2003-09-03 EP claimed
EP-1223918-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING A HMG COA REDUCTASE INHIBITOR AstraZeneca AB (SE) 2002-07-24 EP claimed
WO-2002041895-A1 USE OF ROSUVASTATIN (ZD-4522) IN THE TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA ASTRAZENECA AB (SE) 2002-05-30 WO claimed
WO-2001054668-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING A HMG REDUCTASE INHIBITOR ASTRAZENECA AB (SE) 2001-08-02 WO claimed
EP-0300249-B1 7-[1H-pyrrol-3-yl]-substituted 3,5-dihydroxy-heptane acids, their corresponding delta-lactones and salts, processes for their manufacture, their use as medicines, pharmaceutical preparations and intermediates HOECHST AKTIENGESELLSCHAFT (DE) 1993-02-03 EP claimed
JP-10067744-A None JP disclosed
US-11466252-B2 Expansion and differentiation of inner ear supporting cells and methods of use thereof MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2022-10-11 US disclosed
WO-2021217740-A1 COMPOSITIONS AND METHODS FOR INHIBITING VIRUS INFECTION SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2021-11-04 WO disclosed
WO-1991018903-A1 PYRROLOPYRIDAZINE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-12-12 WO disclosed
US-5055484-A Anticholesterol and antilipemic agent HOECHST AKTIENGESELLSCHAFT (DE) 1991-10-08 US disclosed
EP-0252476-A2 Trans-6-[2-(N-heteroaryl-3,5-disubstituted) pyrazol-4-yl)-ethyl]- or ethenyl] tetrahydro-4-hydroxypyran-2-one-derivatives a process for their preparation and the use thereof WARNER-LAMBERT COMPANY (US) 1988-01-13 EP disclosed